Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00034463 · ClinicalTrials.gov registry record · Phase 1
ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00034463: Completed Phase 1 study, sponsored by Eli Lilly and Company.
NCT00034463 is a Phase 1 study that has completed, run by Eli Lilly and Company. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00034463, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
This is a non-randomized, phase 1, study with the primary objective of determining the toxicities and establishing the maximum tolerated dose of ALIMTA when administered as a 10 minute infusion every 21 days with folic acid or multi-vitamin supplementation therapy in lightly or heavily pre-treated patients with locally advanced or metastatic cancer.
Interventions
- DRUG ALIMTA
- DRUG folic acid
- DRUG multi-vitamins
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 1 |
What the finished NCT00034463 record still lists
NCT00034463 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which ALIMTA is the first listed.
NCT00034463 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00034463 about?
NCT00034463 is a clinical study titled "ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer". This is a non-randomized, phase 1, study with the primary objective of determining the toxicities and establishing the maximum tolerated dose of ALIMTA when administered as a 10 minute infusion every 21 days with folic acid or multi-vitamin supplementation therapy in lightly or heavily pre-treated p...
What is the current status of trial NCT00034463?
This trial is currently completed. It is a Phase 1 study.
What interventions are being tested in trial NCT00034463?
The interventions under investigation include: ALIMTA (DRUG), folic acid (DRUG), multi-vitamins (DRUG).
Who is sponsoring clinical trial NCT00034463?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.